Cannabigerol (CBG) In The Treatment Of Seizures And Epilepsy

Tech ID: 32966 / UC Case 2022-512-0

ABSTRACT

Researchers at the University of California, Davis have developed a method of treating or mitigating seizure, treating epilepsy, as well as a method of reducing the frequency of seizures, using cannabigerol or dihydrocannabigerol and analogs thereof.

FULL DESCRIPTION

Cannabidiol (CBD), a biologically active constituent of the cannabis (hemp) plant, has been approved for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberoussclerosis complex. Using a standard model in the identification of antiseizure agents, CBD has been shown to protect against tonic hindlimb extension (THLE). Although CBD has been extensively studied, many other plant cannabinoids, including cannabigerol (CBG) and cannabichromene (CBC) previously have not been assessed for potential utility in epilepsy therapy.

Researchers at the University of California, Davis, have assessed cannabigerol (CBG) and cannabichromene (CBC) for potential utility in epilepsy therapy. Utilizing a well-validated model to identify antiseizure agents, they have developed a method of treating or mitigating seizure, treating epilepsy, as well as a method of reducing the frequency of seizures via a therapeutically effective compound of formula.

APPLICATIONS

- Treating or mitigating convulsant effects
- Treating or mitigating seizures
- Treating or mitigating epilepsy

FEATURES/BENEFITS

- Reducing the frequency of seizures
- Potential to benefit large population of epilepsy patients

PATENT STATUS

Country	Type	Number	Dated	Case
Patent Cooperation Treaty	Reference for National Filings	WO 2023/077146	05/04/2023	2022-512

Patent Pending

CONTACT

Raj Gururajan
rgururajan@ucdavis.edu
tel: 530-754-7637.

INVENTORS

- Dhir, Ashish
- Mascal, Mark J.
- Rogawski, Michael A.

OTHER INFORMATION

KEYWORDS

seizure, epilepsy, anticonvulsant, antiseizure medication, cannabigerol, cannabinoid

CATEGORIZED AS

- **Medical**
  - Disease: Central Nervous System
  - Disease: Genetic Diseases and Dysmorphic Syndromes
  - New Chemical Entities, Drug Leads
  - Other
  - Therapeutics

RELATED CASES

2022-512-0

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- Edible Oils to Enhance the Absorption of Orally Administered Steroids Including Neurosteroids
- Preparation of Furan Fatty Acids from 5-(Chloromethyl) Furfural
- Synthetic, Non-Scheduled, Cannabinoid for Reducing the Frequency and Severity of Seizure
- Azocino[4,5,6-cd]Indoles, Methods for Preparation and Medical Use Thereof: Simplified Synthetic Access to a New Class of 5-HT Ligands
- Intranasal Delivery of Allopregnanolone
- Process for Converting Waste Biomass
- 1-(Benzo[1,2-b:4,5-b']Difuran-4-yl)alkyl-2-amines and 1-(2,3,6,7-Tetrahydrobenzo[1,2-b:4,5-b']Difuran-4-yl)butan-2-amines as Serotonin Receptor Modulators for Neurodegenerative Disorders

University of California, Davis
Technology Transfer Office
1 Shields Avenue, Mrak Hall 4th Floor,
Davis,CA 95616

Tel:
530.754.8649
techtransfer@ucdavis.edu
https://research.ucdavis.edu/technology-transfer/
Fax:
530.754.7620